Form 4: Thermo Fisher EVP Sells Shares Under 10b5-1 Plan

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti disposed of 814.702 shares of common stock at $489.74 per share under a pre-arranged 10b5-1 plan.

Summary

• Gianluca Pettiti, Executive Vice President of Thermo Fisher Scientific Inc. (TMO), reported a disposition of common stock.
• The transactions occurred on August 28, 2025, and involved four separate dispositions totaling 814.702 shares.
• Each disposition was executed at a price of $489.74 per share.
• The transactions were marked with code 'F', indicating a disposition to cover tax withholding obligations.
• Following these transactions, Mr. Pettiti directly beneficially owns 21,552.223 shares of Thermo Fisher Scientific common stock.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction for tax purposes, not indicative of significant positive or negative sentiment regarding the company's prospects or operational performance.

Positives

• The disposition of shares was conducted under a Rule 10b5-1 plan, indicating a pre-arranged trading strategy and reducing concerns about opportunistic insider trading.
• The transaction is a routine event, typically associated with tax withholding upon the vesting of equity awards, rather than a discretionary sale based on new negative information.

Negatives

• The transaction represents insider selling, which, while routine for tax purposes, is still a reduction in direct ownership by a key executive.

Future Outlook

N/A

Industry Context

Insider transactions, particularly those involving dispositions for tax purposes under Rule 10b5-1 plans, are common occurrences for executives at large, publicly traded companies. These plans allow insiders to sell a predetermined number of shares at a predetermined time or price, providing an affirmative defense against insider trading allegations and facilitating the management of equity compensation and tax obligations.

Comparison to Industry Standards

• This type of transaction is standard practice for executives managing their equity compensation. Similar tax-related dispositions under 10b5-1 plans are routinely observed at peer companies in the life sciences and healthcare sectors, such as Danaher Corporation, Agilent Technologies, and Becton, Dickinson and Company.

Corporate Governance

Stakeholder Impact

• Shareholders: May note the insider selling, but the 10b5-1 plan mitigates concerns about the executive's confidence in the company. The impact on share price is likely minimal due to the routine nature of the transaction.
• Management: The transaction reflects a standard process for managing executive compensation and tax liabilities.

Key Dates

Recommendation

The filing details a routine insider stock disposition for tax purposes under a 10b5-1 plan. This is a common practice and does not provide new fundamental information about Thermo Fisher Scientific Inc. to warrant a change in investment recommendation. The transaction itself is neutral to the company's operational performance or future outlook.

Keywords

Thermo Fisher Scientific, TMO, Insider Transaction, Form 4, Beneficial Ownership, Stock Disposition, Executive Compensation, 10b5-1 Plan, Gianluca Pettiti